Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We report dose-escalation results from an open-label, phase 1/2 trial evaluating avelumab (anti-PD-L1) in paediatric patients with refractory/relapsed solid tumours. METHODS: In phase 1, patients aged < 18 years with solid (including central nervous system [CNS]) tumours for which standard therapy did not exist or had failed were enrolled in sequential cohorts of 3-6 patients. Patients received avelumab 10 or 20 mg/kg intravenously every 2 weeks. Primary endpoints were dose-limiting toxicities (DLTs) and grade ≥ 3 treatment-emergent adverse events (AEs). RESULTS: At data cut-off (27 July 2021), 21 patients aged 3-17 years had received avelumab 10 mg/kg (n = 6) or 20 mg/kg (n = 15). One patient had three events that were classified as a DLT (fatigue with hemiparesis and muscular weakness associated with pseudoprogression; 20 mg/kg cohort). Grade ≥ 3 AEs occurred in five (83%) and 11 (73%) patients in the 10 and 20 mg/kg cohorts, respectively, and were treatment-related in one patient (7%; grade 3 [DLT]) in the 20 mg/kg cohort. Avelumab exposure in paediatric patients receiving 20 mg/kg dosing, but not 10 mg/kg, was comparable or higher compared with approved adult dosing (10 mg/kg or 800 mg flat dose). No objective responses were observed. Four patients with CNS tumours (20 mg/kg cohort) achieved stable disease, which was ongoing in two patients with astrocytoma at cut-off (for 24.7 and 30.3 months). CONCLUSION: In paediatric patients with refractory/relapsed solid tumours, avelumab monotherapy showed a safety profile consistent with previous adult studies, but clinical benefits were limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To date, limited antitumor activity with ICI monotherapies and dual PD-(L)1 and CTLA-4 inhibitor regimens has been observed in pediatric solid tumors (3, 6–8, 10–12).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several phase I/II studies of ICI monotherapies (ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab) and combination regimens (nivolumab plus ipilimumab) have been conducted in pediatric populations, but limited antitumor activity has been observed, with objective response rates ranging from 0% to 5.9% for children with a solid tumor, including sarcoma.”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
Self-citationAvelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236
Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30671-0 · Cited by 357
Self-citationDavis, K. L., Fox, E., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30023-1 · Cited by 337 · cited 1×
“Limited data are available on paediatric patients with CNS tumours treated with other ICIs because trials generally exclude these patients [4, 5].”
BackgroundJi, Y., & Wang, S.-J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.7903 · Cited by 183
Geoerger, B., Zwaan, C. M., Marshall, L. V., Michon, J., Bourdeaut, F., Casanova, M., Corradini, N., Rossato, G., Farid-Kapadia, M., Shemesh, C. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30693-x · Cited by 171 · cited 8×
“Grade 1/2 IRRs occurred in 33% in the 10 mg/kg cohort and 47% in the 20 mg/kg cohort, and no grade ≥ 3 IRRs occurred.”
BackgroundResultInfluentialPseudoprogression and hyperprogression after checkpoint blockade
Wang, Q., Gao, J., & Wu, X. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.018 · Cited by 163
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 151
Cited by
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296341 · Cited by 216
Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0411 · Cited by 74
Self-citationvan Bree, N. F. H. N., & Wilhelm, M. (2022) · Cancers · doi:10.3390/cancers14205009 · Cited by 36
Belgiovine, C., Mebelli, K., Raffaele, A., Cicco, M. D., Rotella, J., Pedrazzoli, P., Zecca, M., Riccipetitoni, G., & Comoli, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063225 · Cited by 25
van Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19
Metadata
- Authors
- Loeb, D. M., Lee, J. W., Morgenstern, D. A., Samson, Y., Uyttebroeck, A., Lyu, C. J., Van Damme, A., Nysom, K., Macy, M. E., Zorzi, A. P., Xiong, J., Pollert, P., Joerg, I., Vugmeyster, Y., Ruisi, M., & Kang, H. J.
- Affiliations
- Children's Hospital at Montefiore (US)
- Samsung Medical Center (KR)
- University of Toronto (CA)
- Centre Hospitalier Universitaire Sainte-Justine (CA)
- KU Leuven (BE)
- Yonsei University (KR)
- Rigshospitalet (DK)
- Children's Hospital Colorado (US)
- London Health Sciences Centre (CA)
- Merck Healthcare KGaA, Darmstadt (Germany) (DE)
- Seoul National University (KR)
- Corresponding author
- Kang, Hyoung Jin
- ORCID
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2022-03-09
- Volume
- 71
- Issue
- 10
- Pages
- 2485-2495
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC9463244
- OpenAlex
- W4220919246
- Cited by
- 21
- References
- 20
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 6 · 2023: 8 · 2022: 2
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Scholarship@Western (Western University) (submittedVersion)
- Lirias (submittedVersion, cc-by)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Merck KGaA
- Pfizer
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- avelumab, PD-L1 inhibitors, pediatric solid tumors, dose escalation, dose-limiting toxicity, treatment-emergent adverse events, central nervous system tumors, astrocytoma, immunotherapy safety, drug exposure
- MeSH terms
- Child, Fatigue, Humans, Neoplasms, Cohort Studies, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial. https://app.cochat.ai/papers/10.1007/s00262-022-03159-8
- The paper
- Loeb, D. M., Lee, J. W., Morgenstern, D. A., Samson, Y., Uyttebroeck, A., Lyu, C. J., Van Damme, A., Nysom, K., Macy, M. E., Zorzi, A. P., Xiong, J., Pollert, P., Joerg, I., Vugmeyster, Y., Ruisi, M., & Kang, H. J. (2022). Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial. Cancer Immunology Immunotherapy. https://doi.org/10.1007/s00262-022-03159-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.